Tianjin China-U.S. Bayer Pharmaceutical Co., Ltd.
Tianjin, China-U.S. Bayer Pharmaceutical Co., Ltd. (CUPB) is a joint venture between Tianjin Pharmaceutical Group Co., Ltd. and Bayer Healthcare Co., Ltd., which was established in 2004 and located in Tianjin Economic and Technological Development Area. With the joint efforts of both sides, the company has developed into one of the leading modern pharmaceutical enterprises in China.
CUPB has access to Bayer’s comprehensive technological advantage, including an R&D team of over 400 scientists and rich experiences in pharmaceutical industry. Our innovative research capabilities have made CUPB an important partner for Bayer in the development of innovative drugs with excellent quality. We have an advanced production system that ensures compliance with national GMP regulations and high-quality products.
At CUPB, we focus on the research and development of innovative drugs, including vaccines and biotechnology products. Our R&D team has already conducted drug research activities in cardiovascular, metabolic and mental health fields. We are committed to research and develop exclusive products in the domestic and foreign markets.
In addition to drug research and development, CUPB is also devoted to social and economic contributions to local communities. We have established a Charitable Fund to support medical and health activities and local charities. We also cooperate with local universities and have established very close collaboration with the research centers at Jiaotong University and Nankai University.
We remain dedicated to providing consumers worldwide with innovative, high-quality medicines. With our rich experiences in drug research and extensive technological resources, we believe that we can continue our success and enhance our leadership role in the pharmaceutical industry.
